QuidelOrtho (NASDAQ:QDEL) Releases FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.070-2.570 for the period, compared to the consensus EPS estimate of 2.450. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.

QuidelOrtho Price Performance

Shares of NASDAQ:QDEL traded down $1.53 during trading on Wednesday, hitting $39.94. 1,309,639 shares of the stock were exchanged, compared to its average volume of 889,851. The company has a market cap of $2.69 billion, a PE ratio of -1.43 and a beta of 0.08. The company has a current ratio of 1.38, a quick ratio of 0.81 and a debt-to-equity ratio of 0.68. The company has a fifty day moving average price of $43.28 and a two-hundred day moving average price of $42.36. QuidelOrtho has a 12-month low of $29.74 and a 12-month high of $68.85.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Wednesday, February 12th. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. On average, analysts forecast that QuidelOrtho will post 1.73 EPS for the current year.

Analysts Set New Price Targets

QDEL has been the subject of several recent research reports. William Blair restated a “market perform” rating on shares of QuidelOrtho in a report on Wednesday, November 20th. StockNews.com raised shares of QuidelOrtho from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Jefferies Financial Group initiated coverage on QuidelOrtho in a research note on Tuesday, December 10th. They issued a “hold” rating and a $43.00 target price on the stock. Finally, Citigroup upgraded QuidelOrtho from a “neutral” rating to a “buy” rating and increased their target price for the company from $44.00 to $50.00 in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, QuidelOrtho presently has a consensus rating of “Hold” and an average price target of $53.43.

Insider Buying and Selling

In related news, CEO Brian J. Blaser acquired 6,033 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was bought at an average price of $41.42 per share, with a total value of $249,886.86. Following the purchase, the chief executive officer now directly owns 6,033 shares in the company, valued at $249,886.86. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $35.31, for a total transaction of $291,667,061.73. The disclosure for this sale can be found here. 1.00% of the stock is owned by company insiders.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.